Clinical studies have shown that NSCLC patients treated with combined HDAC inhibitors (HDACi) and ICIs derive clinical benefit,[38, 39] suggesting that HDAC4‐mediated deacetylation may contribute to resistance in low LIRA‐score patients.[40]. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.